NCT04630860View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

May 12, 2021

Study Completion Date

January 25, 2022

Conditions
Parkinson Disease
Interventions
DRUG

LY03003

Rotigotine,extended-release microspheres

Trial Locations (1)

Unknown

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT04630860 - A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD | Biotech Hunter | Biotech Hunter